Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Biosimilars: SOP for Resin Life Cycle Management – V 2.0

Posted on By


Biosimilars: SOP for Resin Life Cycle Management – V 2.0


Standard Operating Procedure for Resin Life Cycle Management in Biosimilar Manufacturing

Department Biosimilars
SOP No. SOP/BS/167/2025
Supersedes SOP/BS/167/2022
Page No. Page 1 of 11
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To define the procedure for managing the complete life cycle of chromatography resins used in biosimilar manufacturing, including usage tracking, regeneration, performance monitoring, and safe disposal to ensure GMP compliance and consistent product quality.

2. Scope

This SOP applies to all types of chromatography resins (e.g., Protein A, ion exchange, hydrophobic interaction, size exclusion) used in downstream purification of biosimilar products in pilot and commercial scale facilities.

3. Responsibilities

  • Production: Track resin usage, complete regeneration and storage, and maintain resin logs.
  • QA: Review and approve resin performance trends and life cycle records.
  • Validation: Qualify new resin lots and evaluate reuse limits based on product-specific data.

4. Accountability

The Head of Downstream Manufacturing is accountable for ensuring resin use is within approved life cycle limits and all records are maintained and reviewed for regulatory inspections.

5. Procedure

5.1 Resin Receipt and Qualification

  1. Receive resin with COA and ensure label integrity and lot traceability.
  2. Assign a unique Resin ID and enter into the Resin Inventory Log (Annexure-1).
  3. Conduct acceptance testing as per validation protocol (e.g., binding capacity, microbial limit).

5.2 Resin Usage Tracking

  1. Track resin usage batch-wise in the Resin Use Log (Annexure-2).
  2. For each cycle, document:
    • Batch No.
    • Cleaning and sanitization agent used
    • Number of reuse cycles completed
    • Performance characteristics (binding capacity, pressure drop)

5.3 Regeneration and Sanitization

  1. After each use, clean resin using validated CIP protocols (refer to individual resin cleaning SOPs).
  2. Sanitize resin with 0.5 M NaOH for 30 min contact time or as per manufacturer’s recommendation.
  3. Flush with WFI until pH neutral and store in 20% ethanol buffer at 2–8°C.

5.4 Performance Monitoring

  1. At defined intervals (e.g., every 10th cycle), perform:
    • Dynamic Binding Capacity (DBC) test
    • Column pressure profile
    • Visual inspection of resin
  2. Compare results against initial baseline values.
  3. Document findings in the Resin Performance Evaluation Sheet (Annexure-3).

5.5 Reuse Limits and Retirement Criteria

  1. Set reuse limits based on process validation (e.g., 100 cycles for Protein A).
  2. Retire resin when:
    • Binding capacity drops by > 20% from initial value
    • Increased back pressure beyond spec
    • Resin discoloration or physical degradation
  3. Record resin retirement in Annexure-4 and update inventory status as ‘Obsolete’.

5.6 Resin Disposal

  1. Dispose of expired or damaged resin as per SOP for Hazardous Waste Disposal.
  2. Label containers clearly and ensure transport to authorized waste treatment facility.

6. Abbreviations

  • DBC: Dynamic Binding Capacity
  • COA: Certificate of Analysis
  • CIP: Clean-In-Place
  • WFI: Water for Injection

7. Documents

  1. Resin Inventory Log – Annexure-1
  2. Resin Use Log – Annexure-2
  3. Resin Performance Evaluation Sheet – Annexure-3
  4. Resin Retirement Record – Annexure-4

8. References

  • ICH Q9 – Quality Risk Management
  • WHO TRS 999 – GMP for Biotherapeutics
  • OEM Resin Use Guidelines (GE, Repligen, Cytiva)

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Resin Inventory Log

Resin ID Resin Type Lot No. Vendor Received Date Status
RES-QA-101 Protein A PA-4521 Cytiva 01/03/2025 Active

Annexure-2: Resin Use Log

Cycle No. Batch No. Date Sanitization Performed Operator
1 BS-MAB-022 04/03/2025 Yes Ajay Verma

Annexure-3: Resin Performance Evaluation Sheet

Cycle Binding Capacity Pressure Drop Observations Result
10 92% 1.2 bar No change Acceptable

Annexure-4: Resin Retirement Record

Resin ID Reason for Retirement Retirement Date Disposed By
RES-QA-088 Binding loss > 20% 01/05/2025 Sunita Reddy

Revision History:

Revision Date Revision No. Details Reason Approved By
04/05/2025 2.0 Included detailed resin performance metrics and disposal guidelines Process harmonization
See also  Biosimilars: SOP for Back-Up Seed Train Planning - V 2.0
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: Sterile Injectable Manufacturing: SOP for Troubleshooting Autoclave Issues in Sterilization – V 2.0
Next Post: How to Write SOPs for Complex Operations and Equipment

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version